# Rare case report: sclerosing epithelioid fibrosarcoma with FUS-CREB3L1 gene fusion

**Authors:** Tingting Wang, Haimin Xu, Chuanying Li

PMC · DOI: 10.3389/fonc.2025.1491398 · 2025-03-12

## TL;DR

A rare case of sclerosing epithelioid fibrosarcoma is reported, highlighting diagnostic challenges due to overlapping features with another tumor type.

## Contribution

The case demonstrates the presence of FUS-CREB3L1 gene fusion in SEF despite distinct histological features.

## Key findings

- Histomorphological analysis confirmed pure SEF without myxoid stroma.
- NGS revealed FUS-CREB3L1 gene fusion, typically associated with low-grade fibromyxoid sarcoma.
- The case highlights diagnostic challenges due to asynchrony between morphology and molecular features.

## Abstract

Sclerosing epithelioid fibrosarcoma (SEF) is a rare soft tissue malignancy frequently misdiagnosed due to its overlapping immunohistochemical and molecular features with low-grade fibromyxoid sarcoma (LGFMS). We present the case of a 60-year-old male who initially presented with a mass in the left thigh four years ago, which significantly increased in size over the past year. MRI of the femur revealed a large, well-circumscribed mass in the mid and lower left thigh. Surgical excision of the tumor and associated thrombus in the ipsilateral blood vessel was performed. Histomorphological analysis confirmed a pure SEF with no myxoid stroma, aiding in its differentiation from LGFMS. Immunohistochemical staining revealed diffuse and strong MUC4 positivity, while next-generation sequencing (NGS) demonstrated molecular characteristics consistent with LGFMS, specifically FUS-CREB3L1 gene fusion. This case underscores the asynchrony between the pathological morphology and molecular features of soft tissue tumors during their development and differentiation. Although histologically low-grade, SEF typically exhibits a high rate of local recurrence and distant metastasis. We diagnosed this case as SEF and recommended an aggressive clinical treatment regimen. This report aims to raise awareness of the diagnostic challenges associated with SEF and LGFMS.

## Linked entities

- **Diseases:** low-grade fibromyxoid sarcoma (MONDO:0006272)

## Full-text entities

- **Genes:** FUS (FUS RNA binding protein) [NCBI Gene 2521] {aka ALS6, ETM4, FUS1, HNRNPP2, POMP75, TLS}, CREB3L1 (cAMP responsive element binding protein 3 like 1) [NCBI Gene 90993] {aka C16DELp11.2, DEL16p11.2, OASIS, OI16}, MUC4 (mucin 4, cell surface associated) [NCBI Gene 4585] {aka ASGP, HSA276359, MUC-4}
- **Diseases:** tumor (MESH:D009369), SEF (MESH:D005354), fibromyxoid sarcoma (MESH:D012509), LGFMS (MESH:D036821), soft tissue malignancy (MESH:D012983), metastasis (MESH:D009362), thrombus (MESH:D013927)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11936928/full.md

---
Source: https://tomesphere.com/paper/PMC11936928